Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency

Clinical trial NCT02789332 · COMPLETED

Trial details

NCT number: NCT02789332
Sponsor: GBG Forschungs GmbH
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Cancer Triple Negative Breast Neoplasms HRpos Breast Neoplasms BRCA 1 /2 and / or HRD

Start date: 2016-09-01
Primary completion: 2019-02-01
Enrollment: 107

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.